Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179520 | 0.88 | KDM4E (0.33) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10179697 | 0.81 | LMNA (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10179930 | 0.78 | HTT (0.32) | MAPTMEN1LMNAHTTKMT2A | |
| SCHEMBL10180149 | 0.73 | PTPN1 (0.35) | F2RL3MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10180937 | 0.73 | GRIN2D (0.36) | F2RL3MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10181382 | 0.73 | TSHR (0.51) | F2RL3MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10180581 | 0.73 | MEN1 (0.37) | MEN1LMNAHTTKMT2A | |
| SCHEMBL6658253 | 0.69 | ALDH1A1 (0.53) | F2RL3MAPTMEN1KMT2A | |
| SCHEMBL28041429 | 0.68 | NPC1 (0.38) | F2RL3MAPTMEN1LMNAHTT | |
| SCHEMBL28041426 | 0.68 | HPGD (0.43) | MAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474536-B1 | PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF | IHARA CHEMICAL IND CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20120178931-A1 | PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2474536-A1 | PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF | Ihara Chemical Industry Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178931-A1 | PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF | DPYD, UMPS, PNP | F2RL3 3839/4885MAPT 4300/4885GRIN2D 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.